Systematic review on inhaled corticosteroid monotherapy and its efficacy and safety in longterm treatment of patients with chronic obstructive pulmonary disease (COPD) by Buchberger, Barbara et al.
econstor
www.econstor.eu
Der Open-Access-Publikationsserver der ZBW – Leibniz-Informationszentrum Wirtschaft
The Open Access Publication Server of the ZBW – Leibniz Information Centre for Economics
Nutzungsbedingungen:
Die ZBW räumt Ihnen als Nutzerin/Nutzer das unentgeltliche,
räumlich unbeschränkte und zeitlich auf die Dauer des Schutzrechts
beschränkte einfache Recht ein, das ausgewählte Werk im Rahmen
der unter
→  http://www.econstor.eu/dspace/Nutzungsbedingungen
nachzulesenden vollständigen Nutzungsbedingungen zu
vervielfältigen, mit denen die Nutzerin/der Nutzer sich durch die
erste Nutzung einverstanden erklärt.
Terms of use:
The ZBW grants you, the user, the non-exclusive right to use
the selected work free of charge, territorially unrestricted and
within the time limit of the term of the property rights according
to the terms specified at
→  http://www.econstor.eu/dspace/Nutzungsbedingungen
By the first use of the selected work the user agrees and
declares to comply with these terms of use.
zbw
Leibniz-Informationszentrum Wirtschaft
Leibniz Information Centre for Economics
Buchberger, Barbara; Niebuhr, Dea; Kossmann, Beate; Wasem, Jürgen;
Neumann, Anja
Working Paper
Systematic review on inhaled corticosteroid monotherapy and its
efficacy and safety in longterm treatment of patients with chronic
obstructive pulmonary disease (COPD)
Diskussionsbeitrag aus der Fakultät Wirtschaftswissenschaften der Universität Duisburg-
Essen, Campus Essen, No. 192
Provided in cooperation with:
Universität Duisburg-Essen (UDE)
Suggested citation: Buchberger, Barbara; Niebuhr, Dea; Kossmann, Beate; Wasem, Jürgen;
Neumann, Anja (2011) : Systematic review on inhaled corticosteroid monotherapy and its
efficacy and safety in longterm treatment of patients with chronic obstructive pulmonary disease
(COPD), Diskussionsbeitrag aus der Fakultät Wirtschaftswissenschaften der Universität
Duisburg-Essen, Campus Essen, No. 192, http://hdl.handle.net/10419/55144  1 FAKULTÄT
WIRTSCHAFTSWISSENSCHAFTEN
  
Systematic review on inhaled corticosteroid 
monotherapy and its efficacy and safety in long-
term treatment of patients with chronic 








Anja Neumann   2
  
Systematic review on inhaled corticosteroid 
monotherapy and its efficacy and safety in long-
term treatment of patients with chronic 
obstructive pulmonary disease (COPD) 
 
Dr. Barbara Buchberger, MPH1 (barbara.buchberger@medman.uni-due.de) 
Prof. Dr. Dea Niebuhr2 (dea.niebuhr@pg.hs-fulda.de) 
Dipl. Biol. Beate Kossmann, MPH3 (b.kossmann@carem.de) 
Prof. Dr. Jürgen Wasem1 (juergen.wasem@medman.uni-due.de) 
Dr. Dr. Anja Neumann1 (anja.neumann@medman.uni-due.de) 
 
1Alfried Krupp von Bohlen und Halbach-Stiftungslehrstuhl für Medizinmanagement, Universität Duisburg-Essen, 
Essen, Germany 
2Fachbereich Pflege und Gesundheit, Hochschule Fulda, Fulda, Germany 
3 Carem GmbH, Sauerlach, Germany  








Dezember 2011   3
Abstract ..........................................................................................................................................................................  4 
Zusammenfassung ........................................................................................................................................................  5 
1. Introduction ..............................................................................................................................................................  6 
2. Methods .....................................................................................................................................................................  6 
3. Results ........................................................................................................................................................................  7 
3.1. Quality of publications included ...................................................................................................................  7 
3.2. Exacerbations  ....................................................................................................................................................  8 
3.3. Mortality/fatality ...............................................................................................................................................  9 
3.4. Adverse Events  .................................................................................................................................................  9 
4. Discussion  ............................................................................................................................................................... 10 
Conclusion .................................................................................................................................................................. 12 
Abbreviations used ................................................................................................................................................... 12 
Conflicts of interest .................................................................................................................................................. 12 
References .................................................................................................................................................................. 13 
Figure 1. Flowchart on selection of publications included .............................................................................. 16 
Table 1 Patient demographic characteristics, study duration, dosing  ........................................................... 17 
Table 2 Publication quality ...................................................................................................................................... 18 
Table 3 Exacerbations budesonide vs. placebo .................................................................................................. 19 
Table 4 Exacerbations fluticasone vs. placebo ................................................................................................... 20 
Table 5 Exacerbations beclomethasone vs. placebo  ......................................................................................... 21 
Table 6 Mortality and fatality  .................................................................................................................................. 21 
Table 7 Adverse events budesonide vs. placebo ............................................................................................... 22 
Table 8 Adverse events fluticasone vs. placebo  ................................................................................................. 23 
Table 9 Adverse events beclomethasone vs. placebo ...................................................................................... 24 
     4
Abstract 
Aim: Chronic obstructive pulmonary disease (COPD) is a leading cause of chronic morbidity and 
mortality throughout the world. Pharmacologic therapy of stable COPD is used to prevent and 
control symptoms, reduce the frequency and severity of exacerbations, improve health status and 
improve exercise tolerance, correlating disease severity. Bronchodilators (beta2-sympathomimetics 
and anticholinergics) are the mainstay of current drug therapy. Theophylline and derivates are 
effective in long-term treatment but are judged to be third-line drugs because of their low 
therapeutic index and several interactions. Continuous therapy with inhaled corticosteroids in 
COPD is controversially discussed. The aim of this systematic review is to assess the efficacy and 
safety of inhaled corticosteroids compared to placebo for the long-term treatment of COPD. 
Methods: We searched the databases MEDLINE, EMBASE and Cochrane Library. Two reviewers 
independently scanned titles and abstracts and decided about the eligibility of articles identified by 
our search regarding preestablished inclusion criteria. Data from eligible articles were extracted 
followed by a qualitative synthesis of information. We assessed the quality of included trials according 
the criteria of the German Institute for Quality and Efficiency in Health Care (IQWiG). 
Results: Our systematic literature search identified 17 studies. For the total rate of exacerbations 
only two out of ten studies showed a statistically significant difference in favour of corticosteroid 
treatment; analyses of oral corticosteroid-treated episodes showed statistically significant differences 
in favour of the active treatment in all studies. Concerning mortality and fatality no differences 
between groups could be ascertained. One study demonstrated a higher risk of developing 
pneumonia after fluticasone treatment than after placebo (p<0,001); other differences between the 
groups regarding adverse events were without clinical relevance. The methodological quality of 
publications was mostly low generally due to missing information, and therefore the validity of 
evidence must be questioned. 
Conclusions: There are indications of an advantage for the corticosteroid treatment in patients 
with COPD, but taking into consideration the methodological flaws with high potential of bias the 
validity of the results has to be considered limited. 
Key words: chronic obstructive pulmonary disease, COPD, corticosteroids, systematic review   5
Zusammenfassung  
Ziel: Die chronisch obstruktive Lungenerkrankung (COPD) ist weltweit eine der Hauptursachen 
chronischer Morbidität und Mortalität. Die medikamentöse Therapie der stabilen COPD dient der 
Verhinderung und Kontrolle von Symptomen, der Reduktion von Häufigkeit und Schwere von 
Exazerbationen sowie der Verbesserung des Gesundheitszustands. Bronchodilatatoren (Beta2-
Sympathomimetika und Anticholinergika) gehören in der Behandlung der COPD zur 
Standardtherapie. Theophyllin und Derivate sind in der Langzeittherapie der COPD effektiv, werden 
aber wegen der geringen therapeutischen Breite und zahlreicher Interaktionen als 
Bronchodilatatoren der dritten Wahl empfohlen. 
Eine Dauerbehandlung mit inhalativ verabreichten Kortikosteroiden ist bei der COPD umstritten. 
Ziel des vorliegenden systematischen Reviews ist die Überprüfung der Wirksamkeit und 
Verträglichkeit von inhalativen Kortikosteroiden im Vergleich zu Placebo in der Langzeit-Therapie 
der COPD. 
Methoden: Eine Literaturrecherche wurde in den Datenbanken MEDLINE, EMBASE und Cochrane 
Library durchgeführt. Die Auswahl der Artikel erfolgte anhand von Titel und Abstract durch zwei 
unabhängige Wissenschaftler mittels a priori festgelegter Einschlusskriterien. Die Daten 
entsprechender Publikationen wurden extrahiert und eine qualitative Informationssynthese wurde 
gebildet. Eine Qualitätsbewertung der eingeschlossenen Publikationen erfolgte anhand der und gemäß 
den Kriterien des Instituts für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). 
Ergebnisse: Durch die systematische Literaturrecherche wurden 17 relevante Studien identifiziert. 
In der Reduktion der Gesamtrate von Exazerbationen zeigte sich nur in zwei von zehn Studien ein 
Vorteil für eine inhalative Kortikosteroid-Behandlung. Hinsichtlich der Häufigkeit von Episoden mit 
oraler Gabe von Kortikosteroiden waren die Gruppenunterschiede in allen Studien zugunsten der 
Kortikosteroid-Behandlung statistisch signifikant. Für die Parameter Mortalität und Letalität konnten 
keine Gruppenunterschiede festgestellt werden. In einer Studie war das Risiko, eine Pneumonie zu 
entwickeln, in der Kortikosteroid-Gruppe größer (p<0,001) als in der Placebo-Gruppe; andere 
Gruppenunterschiede im Auftreten unerwünschter Ereignisse waren klinisch nicht relevant. Die 
methodische Qualität der Publikationen war überwiegend gering, sodass die Validität der Aussagen in 
Frage gestellt werden muss. 
Schlussfolgerung: Es gibt Hinweise auf einen Vorteil zugunsten einer Kortikosteroid-Behandlung 
bei Patienten mit COPD, allerdings schränkt die mangelhafte Qualität der Publikationen mit hohem 
Verzerrungspotential die Aussagekraft der Ergebnisse ein. 
Schlüsselwörter: chronisch obstruktive Lungenerkrankung, COPD, Kortikosteroid, systematischer 
Review   6
1. Introduction 
Chronic obstructive pulmonary disease (COPD) is a leading cause of chronic morbidity and mortality 
throughout the world. COPD is the fourth leading cause of death in the world, and further increases 
in its prevalence and mortality can be predicted in the coming decades because smoking frequencies 
rise and the population ages [1,2]. The disease is characterised by a progressive, not fully reversible 
or partly reversible airflow obstruction based on chronic bronchitis with cough and sputum 
production or emphysema. The major risk factor for the development of COPD is cigarette smoking, 
and the most efficacious therapy and sole possibility for decelerating the progression of the disease 
consists in risk reduction, particularly in stopping tobacco smoking. Pharmacologic therapy of stable 
COPD is used to prevent and control symptoms, reduce the frequency and severity of 
exacerbations, improve health status and improve exercise tolerance, correlating disease severity. 
Bronchodilators (beta2-sympathomimetics, anticholinergics) are the mainstay of current drug 
therapy. Theophylline and derivates are effective in long-term treatment but are judged to be third-
line drugs because of their low therapeutic index and several interactions [3]. Continuous therapy 
with inhaled corticosteroids in COPD is controversially discussed: in contrast to the eosinophilic 
inflammation in asthma bronchiale responding to corticosteroids, patients with COPD show an 
infiltration of bronchial tissue with neutrophilic granulocytes responding less clear to corticosteroids 
[4]. Many trials have shown that ICS improve symptoms and decrease the number of exacerbations 
[5] on the other hand ICS could not demonstrate influence in decline of forced expiratory volume in 
one second [6]. Therefore, recommendations on pharmacological management are different. The aim 
of this systematic review was to assess the efficacy and safety of inhaled corticosteroids (ICS) 
compared to placebo by patient-relevant outcome parameters. 
2. Methods 
We searched the databases MEDLINE, EMBASE and Cochrane Library (in october 2008) using the 
keywords „chronic obstructive lung disease“, „bronchodilating agent“, „budesonide“, „fluticasone“, 
„beclomethasone“, „mometasone“ und „ciclesonide“. We limited the electronic searches to „human” 
and „English Language”. Websites of health technology assessment (HTA) agencies and medical 
societies, bibliographies of included papers, and systematic and not systematic reviews were also 
screened to capture literature relevant to the scope of our topic. 
Two reviewers independently scanned titles and abstracts and decided about the eligibility of articles 
identified by our search. Preestablished inclusion criteria were (1) studies with patients who had 
received a diagnosis COPD, (2) trials that assigned patients to ICS versus ICS or ICS versus placebo, 
(3) trials of at least 3 months’ duration and (4) number of patients per treatment arm >10. We 
excluded abstract publications only and publications of the same study without additional 
information.   7
We extracted data from eligible articles regarding the outcome parameters exacerbations, mortality, 
fatality, adverse events, using standardised documentation sheets generating synthesis of information 
with regards to quality. We assessed the quality of included trials according the criteria of the 
German Institute for Quality and Efficiency in Health Care (IQWiG). Therefore an adequate 
concealment and an adequate intention to treat analysis are the most important aspects as well as 
randomisation, blinding, sample size calculation and withdrawals. Health related quality of life and lung 
function were not analysed. 
 
3. Results 
Overall, 1415 citations were identified, from which 21 fulfilled the inclusion criteria and were 
enclosed in the analysis (Fig. 1). Our literature search identified 17 double blind randomised 
controlled trials with data from 21 publications determining the efficacy and safety of an inhaled 
corticosteroid (ICS) compared with placebo in patients with COPD. Table 1 describes the included 
studies. Seven studies focused on fixed combination therapies with budesonide/formoterol or 
salmeterol/fluticasone compared to the single substances and placebo [7], [8], [9], [10], [11], [12]. 
With exception of the study by Renkema 1996 [13], investigating in addition an ICS combined with 
prednisolone, all other studies were comparing only two therapies. Thompson et al. 2002 [14] used a 
crossover design whereas the other studies had a parallel group design (Table 1) 
 
3.1. Quality of publications included 
The methodological quality of studies was assessed using informations from publications available. 
Except for Calverley et al. 2007 [10], Paggiaro et al. 1998 [15], Vestbo et al. 1999 [16], all 
publications showed gross deficiencies. The procedure of randomisation was not described by 
Calverley et al. 2003a [7], Hanania et al. 2003 [11], Mahler et al. 2002 [12], Pauwels et al. 1999 [17], 
Senderovitz et al. 1999 [18], Szafranski et al. 2003 [8], Verhoeven et al. 2002 [19] und Weir et al. 
1999, [20] and details concerning adequate concealment of treatment allocation were only presented 
by Borbeau et al. 1998 [21] and Paggiaro et al. 1998 [15]- for hiding informations sealed envelopes 
were used. Sample size calculation is not adequately presented by Calverley et al. 2007 [10], Hanania 
et al. 2003 [11], Mahler et al. 2002 [12], Pauwels et al. 1999 [17], Renkema et al. 1996 [13], 
Thompson et al. 2002 [14], Verhoeven et al. 2002 [19] and Weir et al. 1999 [20] either completely 
missing or missing details (e.g. not mentioning level of significance) so that reproducing the sample 
size calculation is impossible. The number of withdrawals is appropriately given by all publications but 
Hanania et al. 2003 [11] not stratifying the reasons for discontinuations according to treatment arms. 
Lack of information about all reasons for withdrawal was given by Hanania et al. 2003 [11], Mahler et 
al. 2002 [12], Renkema et al. 1996 [13], Senderovitz et al. 1999 [18], Szafranski et al. 2003 [8] and   8
Weir et al. 1999 [20]. Remarkable in Szafranski et al. 2003 [8] are 102 patients withdrawn (13%) 
without information about causes.  
All studies with patients of mean COPD disease stage III, classified as a result of baseline lung 
function measurements (FEV1 % predicted) and according to GOLD [1], [21], [22], [7], [9], [11], [12], 
[8], [20], showed high withdrawal rates from 25 bis 53% after placebo and rates from 8 to 44% after 
corticosteroids making systematic bias (attrition bias) possible and resulting in potential distortion of 
the outcomes. Also among the studies with participants of lower disease severity the withdrawal 
rates in Pauwels et al. 1999 [17], Renkema et al. 1996 [13], Vestbo et al. 1999 [16] und Paggiaro et al. 
1998 [15] from 19-35% after placebo and 9-26% after corticosteroids lead to suppose attrition bias; 
in Thompson et al. 2002 [14] and Senderovitz et al. 1999 [18] specifications of disease severity are 
missing, withdrawal rates are only given in total with 31 und 27%. In the publication of Calverley et al. 
2003a [17] the authors themselves are discussing that systematic bias due to high withdrawal rates 
leads to a lower number of exacerbations and that to some extent this bias applies to lung function 
and HRQL differences as well, probably underestimating the reduction in exacerbations concerning 
the treatment with budesonide/formoterol compared to placebo. Following the intention to treat 
principle is adequately described only by Calverley et al. 2007 [10] picturing the method of taking 
into account data from patients withdrawn prematurely. In conclusion and owing to description 
above the quality of publications by Vestbo 1999 [16], Calverley 2007 [10] und Paggiaro 1998 [15] is 
assessed as with low deficiencies and all others as with gross deficiencies (Table 2). 
3.2. Exacerbations 
Ten studies were comparable with regard to the definition of exacerbation [7], [13], [8], [22], [9], 
[10], [11], [15], [14], [23]. From these studies only Burge et al. 2000 [22] and Calverley et al. 2003b 
[9] found statistically significant differences between treatment arms in favour of the inhaled 
corticosteroids compared to placebo treatment. Time to first exacerbation was analysed in four of 
these studies [7], [22], [11], [23], but only the results of van der Valk et al. 2002 [23] showed an 
advantage for ICS with statistically significant differences which must be interpreted cautiously 
because the authors did not mention the methods of calculation for this parameter in the statistical 
analysis section and do not give a p-value, so we only have a wide confidence interval with no precise 
estimation. Five of these studies [7], [8], [22], [9], [10] investigated exacerbations being treated with 
oral corticosteroids. All differences between the two groups were statistically significant and in 
favour of corticosteroids (Table 3, 4, 5). 
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3.3. Mortality/fatality 
Only Calverley et al. 2007 [10] analysed mortality and fatality with stochastic methods. Neither for all 
cause mortality nor for fatality statistically significant differences between the two groups could be 
found (Table 6). 
 
3.4. Adverse Events 
The frequency of adverse events and withdrawals was mostly outlined in publications in a descriptive 
way. In studies lasting less than one year [21], [18], [11], [12], [15], [14], [13], 19] no statistically 
significant differences were found with exception of Paggiaro et al. 1998 [15] and Verhoeven et al. 
2002 [19]. Paggiaro et al. 1998 [15] noticed a lower plasma cortisol concentration after ICS 
compared to placebo (p=0,024) but the authors stated that it was not associated with any clinical 
relevance. In the study of Verhoeven et al. 2002 [19] adverse events relating to airways disease 
and/or study medication were reported more often by patients in the placebo group (p=0,02). 
In the publications of studies with duration of one year [7], [8], [9] statistically significant differences 
in the frequency of withdrawals were described. The patients in Calverley et al. 2003a [7] showed 
significantly more withdrawal due to COPD deterioration after placebo (p=0,031), and the total 
number of withdrawals was higher after placebo (p=0,007) in Calverley et al. 2003b [9]. Szafranski et 
al. 2003 [8] detected a higher number of withdrawals due to COPD deterioration after placebo 
(p<0,05) as well as a higher total number (p<0,05). 
Among publications about studies lasting three years [22], [10], [17], [16]) Burge et al. 2000 
[22],Calverley et al. 2007 [10] and Vestbo et al. 1999 [16] described statistically significant differences 
between groups in the frequency of withdrawals or adverse events. Burge et al. 2000 [22] stated that 
more patients in the placebo group than in the corticosteroid group withdrew because of respiratory 
disease that was not associated with malignancy (p=0,034). Mean cortisol concentrations decreased 
with corticosteroids and increased with placebo (p≤0,032). According to the authors no decreases 
were associated with any signs or symptoms of hypoadrenalism or other clinical effects. The 
probability of having pneumonia was found by Calverley et al. 2007 [10] as being higher after 
corticosteroids than after placebo (p<0,001) and the patients of the placebo group in the study of 
Vestbo et al. 1999 [16] showed a greater frequency of adverse events than the patients of the 
corticosteroid group (p=0,01). None of the publications demonstrated statistically significant 
differences concerning serious systemic side effects e.g. osteoporosis, glaucoma or cataract (Table 7, 
8, 9).   10
4. Discussion 
The aim of this review was to evaluate the safety and efficacy of ICS monotherapy in the long-term 
treatment of patients with COPD that is a matter of ongoing debate.  
We found little evidence that ICS minimize the total exacerbation rates and strong evidence that ICS 
reduce exacerbation rates requiring treatment with oral corticosteroids. Concerning mortality, 
fatality and adverse events no group differences could be found with exception of a higher risk of 
developing pneumonia after fluticasone treatment. 
There are certain limitations with the present systematic review. Our literature search identified only 
randomised controlled trials and studies comparing the ICS budesonide, fluticasone and 
beclomethasone with placebo; studies testing different ICS against each other and other types of 
studies couldn’t be found. For identifying all relevant publications we used a highly sensitive search 
strategy in all relevant data bases followed by hand searches, and internet resources were 
investigated. Nevertheless a systematic error due to incomplete and inadequate reporting 
(publication bias) cannot be excluded. As in any systematic review, publication bias possibly leads to 
overestimation of the associations of ICS treatment with favourable outcomes in COPD. 
The quality of studies assessed by informations available from publications and according to IQWiG 
criteria was very low with exception of Vestbo et al. 1999 [16], Calverley et al. 2007 [10] and 
Paggiaro et al. 1998 [15], therefore conducting meta-analyses and analyses of sensitivity did not seem 
useful. The assessment of study quality in this review is more rigorous as by Yang et al. 2008 [24] and 
Drummond et al. 2008 [25]. The distinctions are based on a much more differenciated judgement of 
study quality according IQWiG standards. While calculating a Jadad-Score Yang et al. 2008 [24] and 
Drummond et al. 2008 [25] only took into account randomisation, blinding and drop outs, and one of 
the most important potential biases in randomised trials, namely allocation concealment [26], was 
not considered. The criteria used in this review can also gather and assess the quality of study 
planning and data analysis and the representation of the precision of results judged on the 
information available from publications. In the systematic review of Singh et al. 2009 [27] the authors 
used the Cochrane Toolkit [26] for the assessment of bias in evaluating each trial for the reporting of 
sequence generation, allocation concealment, the use of blinding of participants and personnel, and 
information on loss to follow up. Concerning the reporting of randomisation sequence generation, 
blinding and the reporting of patients lost to follow-up there are no appraisal differences between the 
present review and that of Singh et al. 2009 [27]. However the assessments of the adequacy of 
allocation concealment differ from each other, with less strictly consequences in the review of Singh 
et al. 2009 [27]. In the Cochrane Toolkit the criteria for the judgement of „No” include the use of an 
open random allocation schedule likewise described by Calverley et al. 2003b [9] using a list of 
patient numbers and a list of treatment numbers and by Burge et al. 2000 [22] using a list with 
treatment numbers, so we assessed the allocation concealment with „not adequate” because of the 
unconcealed information. Vestbo et al. 1999 [16] described an allocation of study numbers in a   11
consecutive order but also without information about hiding, and van der Valk et al. 2002 [23] and 
Calverley 2007 [10] did not report any detail about the allocation concealment only about the 
generation of allocation sequence, therefore we judged the concealment in each case with „No”. The 
differences between the assessement of Singh et al. 2009 [27] and the present review regarding the 
concealment of allocation cannot be solved here, therefore the uncertainty about the concealment 
possibly resulting in biases will remain. 
Seven studies included comparisons of several groups [7], [8], [9], [10], [11], [12], 13] but with 
exception of Calverley 2007 [10] no information is given about the methods of adjustment for 
multiple testing therefore details on statistically significant differences remain questionable. 
Basically placebo comparisons are hiding methodological weakness in the study design: high dropout 
rates in patients with severe disease especially in placebo-groups lead to attrition bias [28], [29] being 
considered and acknowledged in some studies [7], [9] by adjusting sample size calculations for a 
certain dropout rate. This bias creates a causal chain of confounding as the dropout of severely ill 
patients leads to a lower number of exacerbations simultaneously minimizing the frequency of 
hospitalizations, lung function is better and the correlation with quality of life is positively affected 
[30], [31]; in general these drop-outs lead to a healthier study population producing an 
overestimation of the effects. 
One further bias (selection bias) rises already at recruitment of patients for trials with placebo 
groups because severely ill patients in particular must fear being randomised to a placebo group and 
don’t take the risk of frequent exacerbations associated with higher mortality. 
In 10 studies with comparable definition of an exacerbation only Burge et al. 2000 [22] and Calverley 
et al. 2003b [9] detected a statistically significant difference in favour of the corticosteroid treatment 
in total rate of exacerbations. In time to first exacerbation only one of four studies [23] found a 
statistically significant difference with advantage to corticosteroids. Analyses of oral corticosteroid-
treated episodes showed statistically significant differences in favour of the corticosteroids in all five 
studies investigating this outcome. As mentioned above the results are possibly skewed by an 
attrition bias because the dropout rates in the appropriate trials were very high. In summary there is 
some evidence for efficacy of steroid treatment in the reduction of exacerbations only the frequency 
of episodes with oral corticosteroids decreases.Fatality and mortality were solely in one study [10] a 
priori defined outcomes, no statistically significant differences between the groups were found. With 
exception of Calverley et al. 2007 [10] adverse events were only analysed descriptively, and apart 
from known non systemic corticosteroid-related events the authors stated that the frequency of 
adverse events was similar in the two treatment groups. Calverley et al. 2007 [10] reported a higher 
risk of having pneumonia for patients with fluticasone treatment (18,3%) versus patients in the 
placebo group (12,3%), the difference was statistically significant (p<0,001). This is actually important 
because pneumonia in elderly people frequently leads to hospitalizations [28]. 
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Conclusion 
There are indications of an advantage for the inhaled corticosteroid monotherapy in long-term 
treatment of patients with COPD regarding reduced rates of exacerbations with episodes of oral 
corticosteroids. But taking into consideration the methodological flaws with high potential of bias, in 
the main by not mentioning or inadequate allocation concealment and high drop-out rates, the 




AE adverse events, COPD chronic obstructive pulmonary disease, CCLS Copenhagen City Lung 
Study, EUROSCOP European Respiratory Society on chronic obstructive pulmonary disease, FEV1 
forced expiratory volume in one second, HR hazard ratio, HRQL health- related quality of life, HTA 
health technology assessment, ICS inhaled corticosteroids, IQWIG institute for quality and efficiency 
in health care, ISOLDE the Inhaled Steroids in Obstructive Lung Disease in Europe, ITT intention to 
treat, ns not stated, RR relative risk,  SAE serious adverse events, TORCH Towards a Revolution in 
COPD Health, TRISTAN Trial of Inhaled Steroids and long acting beta agonists 
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Table 1 Patient demographic characteristics, study duration, dosing 
 
Study  N ICS  N Control  Age ICSa Age  Controla Duration Dosing 
Budesonide vs. Placebo 
Bourbeau 1998 [21]  39  40  66 (8)  66 (8)  6 M  2x 400 µg bid 
Calverley 2003a [7]  257  256  64 (41-85)b 65  (43-85)b  1 Y  2x 200 µg bid 
Pauwels 1999 EUROSCOP 
[17]  634  643  52,5 (7,5)  52,4 (7,7)  3 Y  1x 400 µg bid 
Renkema 1996 [13]  21  18  56 (8)  54 (10)  2 Y  1x 800 µg bid 
Senderovitz 1999 [18]  37
c  --  58,5 (51-74)
d 62,5  (57-74)
d  6 M  1x 400 µg bid 
Szafranski 2003 [8]  198  205  64 (40-90)b 65  (47-92)b  1 Y  2x 200 µg bid 
Vestbo 1999 CCLS [16]  145  145  59,0 (8,3)  59,1 (9,7)  3 Y  1x 800 µg/1x 
400 µge 
Fluticasone vs. Placebo 
Burge 2000 ISOLDE [22]  376  375  63,7 (7,1)  63,8 (7,1)  3 Y  1x 500 µg bid 
Calverley 2003b TRISTAN 
[9]  374  361  63,5 (8,5)  63,4 (8,6)  1 Y  1x 500 µg bid 
Calverley 2007 TORCH 
[10]  1534  1524  65,0 (8,4)  65, 0 (8,2)  3 Y  1x 500 µg bid 
Hanania 2003 [11]  183  185  63 (40-84)b 65  (40-81) b  6 M  1x 250 µg bid 
Mahler 2002 [12]  168  181  64,4 (42-82)b 64,0  (44-90)b  6 M  1x 500 µg bid 
Paggiaro 1998 [15]  142  139  62 (49-75)b 64  (50-75)b  6 M  2x 250 µg bid 
Thompson 2002 [14]  52  --f 69  (48-80)d --f  6 M  2x 220 µg bid 
van der Valk 2002 [23]  123  121  64,1 (6,8)  64,0 (7,7)  6 M  1x 500 µg bid 
Verhoeven 2002 [19]  10  13  54 (42-65)b 56  (42-67)b  6 M  1x 500 µg bid 
Beclomethasone vs. Placebo 
Weir 1999 [20]  49  49  65,5 (1,0)  67,6 (1,0)  2 Y  4x 250 µg bidg 
a data are presented as mean with standard deviation in parentheses 
b data are presented as mean with range in parentheses 
c only data for the whole study population are presented 
d data are presented as median with range in parentheses 
e morning/evening for 6 M, afterwards 1x 400 µg bid 
f crossover design 
g 3x 250 µg bid for patients weighing < 50 kg 
bid: two times daily, CCLS: Copenhagen City Lung Study, EUROSCOP: European Respiratory Society on chronic 
obstructive pulmonary disease, ISOLDE: the Inhaled Steroids in Obstructive Lung Disease in Europe, M: Months, TORCH: 
TOwards a Revolution in COPD Health, TRISTAN: Trial of Inhaled STeroids ANd long acting beta agonists, Y: Year(s)   18














Budesonide vs. Placebo 
Bourbeau 
1998 [21]  yes/unclear yes  adequate  yes/yes  no  gross 
deficiencies 
Calverley 
2003a [7]  unclear/no yes  adequate yes/yes  unclear gross 
deficiencies 
Pauwels 1999 
[17]  unclear/no yes  inadequate    yes/yes  unclear gross 
deficiencies 
Renkema 
1996 [13]  yes/no yes  no  yes/partial  no  gross 
deficiencies 
Senderovitz 
1999 [18]  unclear/no yes  adequate yes/partial  no  gross 
deficiencies 
Szafranski 
2003 [8]  unclear/no yes  adequate yes/partial  unclear gross 
deficiencies 
Vestbo 1999 
[16]  yes/no yes  adequate  yes/yes  unclear    low 
deficiencies 
Fluticasone vs. Placebo 
Burge 2000 
[22]  yes/no yes  adequate  yes/yes  no  gross 
deficiencies 
Calverley 
2003b [9]  yes/no yes  adequate  yes/yes  unclear  gross 
deficiencies 
Calverley 
2007 [10]  yes/no yes  unclear  yes/yes  yes low 
deficiencies 
Hanania 2003 
[11]  unclear/no yes  inadequate  yes/partial  no  gross 
deficiencies 
Mahler 2002 
[12]  unclear/no yes  inadequate  yes/partial  no  gross 
deficiencies 
Paggiaro 1998 
[15]  yes/unclear yes  adequate  yes/yes  unclear  low 
deficiencies 
Thompson 
2002 [14]  yes/no yes  no  yes/yes  not  relevantg  gross 
deficiencies 
van der Valk 
2002 [23]  yes/no yes  adequate  yes/yes  no  gross 
deficiencies 
Verhoeven 
2002 [19]  unclear/no yes  no  not  relevanth no    gross 
deficiencies 
Beclomethasone vs. Placebo 
Weir 1999 
[20]  unclear/no yes  inadequate  yes/partial  no  gross 
deficiencies 
a unclear: randomisation only mentioned, method not specified 
b no: allocation concealment not mentioned or not adequate, unclear: sealed envelopes used, opaqueness not mentioned 
(or vice versa), yes: sealed and opaque envelopes used or other adequate method e.g. central telephone randomisation 
c double blind def. by Schultz et al. 2002 [32] 
d adequate: endpoint, magnitude of expected effect, power, significance level and calculated sample size are stated, 
inadequate: parts of an adequate sample size calculation are missing, no: sample size calculation is not mentioned 
e unclear: method not specified, ITT-population not clearly identifiable, no: missing considerations about drop-outs  
f no identifiable deficiencies = unimportant deficiencies, low deficiencies = the overall message of the study must not be 
called into question, gross deficiencies = the overall message of the study must be called into question 
g crossover design 
h no drop-outs 
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Table 3 Exacerbations budesonide vs. placebo 
Study Outcomes  ICS  Placebo Group difference 
[95% CI], p-value 
Budesonide vs. Placebo 
Calverley 
2003a [7] 
Definition: need for medical intervention with oral antibiotics and/or corticosteroids or hospitalisation 
Exacerbations/patient/year 
Time to first exacerbation (days)a 
Exacerbations/patient/year 









ns, p= 0,308 
ns, p= 0,512 
 
ns, p= 0,044 
Renkema 
1996 [13] 
Definition: conditions with increased complaints of dyspnea and/or cough and/or sputum production with 
or without fever; treatment with oral corticosteroids, if necessary in combination with antibiotics 
Exacerbations/yeara 
- prestudy year 
- study year 1 
- study year 2 
Exacerbation days study year year a 
- prestudy year 
- study year 1 




























Exacerbations  ns  ns  ns, p > 0,04 
Szafranski 
2003 [8] 
















0,852 [-10,3; 34,1], p= 0,224 
 
[ns], p< 0,001b 
 
[ns], p= 0,045 
Vestbo 1999 
[16] 
Definition: affirmative answer to the question „Have you since your last visit experienced more cough and 
phlegm than usual?“ 
Number of exacerbationsc 155  161  ns,  not  significant d 
no outcome parameter in Bourbeau 1998 [21], Pauwels 1999 [17], Verhoeven 2002 [19] 
a data are presented as median with range in parentheses 
b in favour of ICS 
c absolute values 
d the expression „the difference was not significant“ does not explain whether the clinical or the statistical difference is 
meant 
ns: not stated   20
Table 4 Exacerbations fluticasone vs. placebo 
Study Outcomes  ICS  Placebo  Group  difference 
[95% CI], p-value 
Fluticasone vs. Placebo 
Burge 2000 
[22] 
Definition: worsening of respiratory symptoms that required treatment with oral corticosteroids, or 
antibiotics, or both 
Exacerbations/yeara 
Exacerbations/yearb 
Time to first exacerbation (days)b, d 
Exacerbations/year 
Patients with FEV1 < 50% predictedb, d 
Patients mit FEV1 ≥ 50% predictedb, d 
Exacerbations/patient/year 


















-0,3 [-0,4; 0,0], p= 0,026 c 
ns [0,79; 1,09], p= 0,35 
 
ns [ns], p< 0,022 
ns [ns], p= 0,45 
 
ns [ns], p< 0,001e 
Calverley 
2003b [9] 













ns, p= 0,0001 
Calverley 2007 
[10] 
Definition: symptomatic deterioration requiring treatment with antibiotic agents, systemic 
corticosteroids, hospitalization, or a combination of these 
Exacerbations/year 
moderate or severe 
requiring systemic corticosteroids 










0,82 [0,76; 0,89], p<0,001 
0,65 [0,58; 0,73], p<0,001 
0,88 [0,74; 1,03], p=0,10 
Hanania 2003 
[11] 
Definition: moderate exacerbations requiring treatment with antibiotics and/or corticosteroids, and 
severe exacerbations requiring hospitalization 
Exacerbations 





ns, not significantf 
ns, not significantf 
Mahler 2002 
[12] 
Defined by treatment 
Exacerbations 






not statistically significant 
Paggiaro 1998 
[15] 
Definition: worsening of COPD symptoms, requiring changes to normal treatment, including 
antimicrobial therapy, short courses of oral steroids, and other bronchodilator therapy 
Exacerbations/patient in total  








ns [-0,43; -0,1], p=0,067 
ns. [ns], p< 0,001 
ns. [ns ], p< 0,001 
Thompson 
2002 [14] 
Definition: subjective worsening of chronic baseline dyspnea or cough, accompanied by at least a 25% 
increase in inhaled bronchodilator use and deemed severe enough by the primary care physician to 
require treatment with systemic corticosteroids 
  Number of patients ≥ 1 exacerbation  4  10  ns [ns], p= 0,11 
van der Valk 
2002 [23] 
Definition: worsening of respiratory symptoms that required treatment with a short course of oral 
corticosteroids or antibiotics as judged by the study physician 
 Patients  ≥ 1 exacerbation 
First exacerbation 
Time to first exacerbation (days)a 
 
Second exacerbation 















HR 1,5 [1,05; 2,1], ns 
34,6 [15,4; 53,8], ns 
 
HR 2,4 [1,5; 3,9], ns 
RR 4,4 [1,9; 10,3], ns 
no outcome parameter in Verhoeven et al. 2002 [19] 
a data are presented as mean with standard deviation in parentheses 
b data are presented as median with range in parentheses 
c p-value of test statistic from the non parametric test, separate calculation of the CI  
d publication Jones et al. 2003 [33] 
e in favour of ICS 
f the expression „the difference was not significant“ does not explain whether the clinical or the statistical difference is 
meant 
FEV1 : forced exspiratory volume in one second, HR: hazard ratio, ns: not stated, RR: relative risk   21
Table 5 Exacerbations beclomethasone vs. placebo 
Study Outcomes  ICS  Placebo  Group difference 
[95% CI], p-value 





Exacerbations/yeara  0,36 (0,09)  0,57 (0,13)  ns, not statistically significant 
a data are presented as mean with standard error of the mean in parentheses 
ns: not stated 
 
 
Table 6 Mortality and fatality 
Study Outcomes  Fluticasone  Placebo  Group difference 
[95% CI], p-value 
Fluticasone vs. Placebo 
Calverley 2007 [10]  death from any cause (%) 
COPD related deaths (%) 
cause of death 
- cardiovaskular (%) 
- pulmonary (%) 
- cancer (%) 
- other (%) 

















HR 1,060 [0,886; 1,268] p = 0,53 
HR 1,16 [0,88; 1,53] p = 0,30 
 
ns 
HR: hazard ratio, ns: not stated 
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Table 7 Adverse events budesonide vs. placebo 
Study Drop-Outs*  AE  total  ≥ 1  Number SAE  Drop-out due to AE/ 
deaths 
Budesonide vs. Placebo 




























































Senderovitz 1999d [18] 







































All data are presented as N (%) if possible 
* Drop-Outs: including every discontinuation of the study (withdrawal, drop-out and loss to follow-up) 
a procentual value by own calculation 
b significantly fewer Drop-outs due to COPD worsening in the ICS-group (p=0,031) 
c statistically significant difference (p=0,036)  
d no differentiated presentation given 
e fewer drop-outs due to COPD worsening and all-in rate of drop-outs in ICS-group (p<0,05 each) 
f statistically significant difference (p=0,01)  
AE: adverse events, ns: not stated, SAE: serious adverse events  
 
Table 8 Adverse events fluticasone vs. placebo 
Study Drop-Outs*  AE  total  ≥ 1  Number SAE  Drop-out due to AE/ 
deaths 
Fluticasone vs. Placebo 











































































































































All data are presented as N (%) if possible 
* Drop-Outs: including every discontinuation of the study (withdrawal, drop-out and loss to follow-up)  
a data for the whole randomised phase of study  
b procentual value by own calculation 
c data for the double blind phase of study 
d number of patients with SAE  
e statistically significant difference (p=0,007) 
f only treatment-related AE given 
g related to safety population 
h related to efficacy population (Fluticasone N=1534, Placebo N=1524) 
i incidence AE ≥ 10% 
j data not reported separately for the four treatment arms 
k less reporting of AE related to airways disease and/or study medication in the ICS-group with statistically significant 
differences (18 vs. 7, p=0,02) 






Table 9 Adverse events beclomethasone vs. placebo 
Studie Drop-Outs*  AE  total  ≥ 1  Number 
SAE 
Drop-out due to AE/ 
deaths 
















All data are presented as N (%) if possible 
* Drop-Outs: including every discontinuation of the study (withdrawal, drop-out and loss to follow-up) 
AE: adverse events, ns: not stated, SAE: serious adverse events 
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